APOLLOMICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2046 USD | +4.76% |
|
+1.79% | -78.80% |
| 06-04 | Apollomics Announces Vebreltinib Data At the 2024 American Society of Clinical Oncology Annual Meeting | CI |
| 05-08 | Apollomics, Inc. Appoints Robert Lin to the Board of Directors | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| APOLLOMICS, INC. | Bio Therapeutic Drugs | +4.76% | +1.79% | -78.80% | -95.97% | - | 22.45M |  | | |
Technical Rankings Surperformance
- Stock Market
- Equities
- APLM Stock
- Charts Apollomics, Inc.
- Comparison Chart
